James L. Schaller, M.D.  •  239-263-0133


Common Misunderstandings About Lyme Disease

The Delusion of a Fast Cure

Dr. Stephen Phillips is a doctor's doctor and a man who has served both ill children and adults by serving with great sacrifice in the elite clinical organization of ILADS. Some physicians in ILADS have treated more Lyme and other tick-borne illness patients successfully than entire hospital complexes. Below is just one more example of Dr. Phillips trying to reason clearly about the serious magnitude of Lyme disease. He does so with no benefit other than to serve the citizens of Connecticut and the US. I offer his pearls below with great pride and permission.

Written Testimony of Steven Phillips, MD
Attorney General's Hearing on Lyme Disease
1/29/04

Lyme disease is perfectly positioned to engender controversy. The bacteria that causes the illness, B. burgdorferi, has been exceedingly difficult to grow from Lyme patients with disseminated disease, regardless of their antibiotic treatment status. As a result, there has been no definite laboratory diagnostic test and no concrete definition of cure. If B. burgdorferi could not be cultured from a patient before antibiotic therapy, then there is no reference point with which to compare to indicate whether that individual is cured of the infection after therapy. As such, questions regarding diagnosis, treatment efficacy, and definition of cure, although still lingering problems, were virtual black holes for many years. Because of this prior void of knowledge, early researchers made a series of blind assumptions, many of which, sadly, have proven to be patently invalid. Fortunately, now decades later, there is a wealth of solidly peer reviewed scientific data debunking the prior dogma that Lyme disease is an easily diagnosed and cured illness. Yet, for unknown reasons some of the initial researchers in the field have refused to change their old paradigm in response to the accumulating storehouse of scientific fact, and this has led to a bitter divide in the medical community.

There has been considerable criticism as to the accuracy of currently available antibody blood testing for Lyme disease.1 Seronegative Lyme disease (Lyme with a negative antibody blood test) has been widely reported.2,3,4,5,6,7,8,9,10,11 Analogously, studies demonstrate central nervous system (CNS) infection with B. burgdorferi (the Lyme bacteria) by polymerase chain reaction (PCR) (a DNA test), 10,12,13 antigen capture (a test for Lyme protein),2,3 and culture,10,14,15,16 despite negative cerebrospinal fluid (CSF) by routine Lyme antibody, cell count and chemistries. As such, the absence of antibodies against B. burgdorferi in CSF cannot be relied upon to rule out CNS infection with this organism. Despite these findings, some factions of the scientific community astonishingly continue to place inappropriate emphasis on these obsolete antibody tests for unclear reasons.

Regarding the treatment of Lyme disease, some researchers claim that 30 day courses of antibiotic therapy are curative for even later stage Lyme disease, but it has been impossible for them to prove their claim without a high yield method for culturing B. burgdorferi. However, as difficult as it is to isolate B. burgdorferi from patients with disseminated disease, the reverse can be proven. It has been proven by various methods that 30 day courses of antibiotics are not curative for disseminated Lyme disease in both animal and human clinical trials.

For instance, studies document that 30 day courses of antibiotics do not eradicate disseminated B. burgdorferi infection from dogs.17,18 Unfortunately, and not surprisingly, many humans with late stage Lyme disease do not get cured of their symptoms with 30 day courses of antibiotics. Indeed, there are also many volumes of peer reviewed medical studies demonstrating persistent infection with B. burgdorferi in humans despite multiple and extended courses of aggressive antibiotic therapy. In fact, chronic infection with B. burgdorferi despite both "adequate" and even extensive antibiotic therapy has been demonstrated time and again by both PCR,7,19,20,21,22,23 visualization of the organism by histopathology specimens, 11,23,24,25,26,27,28,29 and despite the well-known difficulties in culturing B. burgdorferi from Lyme patients, by culturing the organism alive from these patients with chronic Lyme disease, most of whom have been seronegative. 15,30,31,32,33,34,35,36,37,38

As a group, pathogenic spirochetes are unusual bacteria. From the infamous Treponema pallidum, which causes syphilis, to the more recently recognized B. burgdorferi, for years they have stimulated debate not only for their breadth of clinical spectrum, but also for a variety of microbiologic incongruities. One such curiosity involves the difficulty in culturing these organisms from infected hosts, yet this may be readily explained once the fundamental life cycles of these bacteria are more fully elucidated, as the following will attempt to achieve in regard to B. burgdorferi.

B. burgdorferi, is frequently described as gram negative (a type of stain for microbiology analysis), microaerophilic (growing best in small amounts of oxygen), spiral in shape, and ranging from 9-32 microns in length, but this narrow definition of the organism cannot logically explain its ability to survive in the divergent conditions existing in the mammal vs. within the tick. If the spiral form was the only rendering in which the bacterium could exist, this relatively large Borrelia should be readily detectable in blood smears of human Lyme disease patients and susceptible infected host animals, yet it is not. As a corollary to this, ticks fed from infected hosts result in very high rates of infected ticks, despite the inability to culture B. burgdorferi routinely from their blood with standard media used to culture the organism from the tick. A logical explanation for these observations is that B. burgdorferi exists in the blood of infected hosts, but in altered states that are quite different from the familiar spiral forms. Logic further dictates that these other forms of the bacteria must not only have different appearances, but also must have unique nutritional and environmental requirements for growth than the archetypal helical forms.

Indeed, B. burgdorferi can exist in a variety of forms, which are ultra-structurally and metabolically distinct. Even in the tick, altered morphological forms of B. burgdorferi are present,39 but selective pressure within the mammal by its immune system results in these altered forms becoming far more common. These "host adapted" forms, referred to collectively as L-forms or spheroplasts, are generally lacking of a cell wall to varying degrees. B. burgdorferi spheroplasts, of which cystic forms and granules are sub-types, have been extensively documented both in vitro (in the test tube),40,41,42,43,44,45 46,47,48,49 and in vivo (in the body) both outside of and within cells.43,50,51,52,53,54 Further to this, their ability to revert from host adapted forms back to helical forms under appropriate conditions has been well documented in vitro. 43,55,56 Since energy expenditure in the way of protein synthesis is required for the conversion into spheroplasts40, the theory that these are merely end stage degenerative forms is implausible. A starving bacterium on its "deathbed" could not expend precious energy on major structural and metabolic changes, unless of course, such action was to ultimately enhance its survival.

Indeed, it has been unequivocally proven that B. burgdorferi cystic forms are virulent and infectious. The infectivity of B. burgdorferi cystic forms, their survival under extreme environmental conditions, and their ability to revert back to helical forms in vivo has been demonstrated by mice inoculation of B. burgdorferi cysts and subsequent recovery of spiral forms from the animals.57 As such, host adapted forms of B. burgdorferi are thought to be critical to the relapsing and chronic nature of the illness.58,59,62

Just as B. burgdorferi spheroplasts have altered metabolic requirements for growth, so too do they have unique antibiotic sensitivities, altered surface protein expression, dramatically reduced surface area presented for immune surveillance, and the ability to cause multiple potential problems for PCR analysis, all as compared to the helical form, respectively, and as such, all of the foregoing helps to explain the observations of antibiotic resistance, seronegativity, and PCR negativity in active disease.47,51,56, 60,61 To elaborate specifically as it pertains to problems with seronegativity, surface proteins of spheroplasts are different than surface proteins of helical forms of B. burgdorferi. Since the current antibody tests are designed to detect reactions to surface proteins of helical forms, these tests are, unfortunately, looking for the wrong targets. This helps to explain the high rates of seronegativity in Lyme disease. To reiterate specifically in regard to B. burgdorferi spheroplasts and altered antibiotic resistance, one very clear example is of cystic forms demonstrating sensitivity to metronidazole (an antibiotic), while their helical kin are resistant.62

As a general rule, chronic bacterial infections must find sanctuary within cells in order to maintain persistence. As such, B. burgdorferi has been documented within a variety of cell types, including but not limited to endothelium (a type of skin cell),63 fibroblasts (connective tissue cells),64 lymphocytes (type of white blood cell),65 macrophages (another type of white blood cell), and keratinocytes (another type of skin cell),47,66 as well as synovium (joint tissue cell).51,67 Such localization within a variety of cells68,69 affords protection against antibiotic destruction and in combination with its ability to convert into spheroplasts, provides B. burgdorferi with a protective arsenal with which it may establish a chronic and persisting infection despite antibiotic therapy.

In light of overwhelming scientific evidence that the B. burgdorferi persists in patients despite extensive treatment, insurance companies and some initial researchers still, without verifiable basis, proclaim patients cured and in no further need of therapy. The real need is to find a definite cure for this illness. However, since many of these researchers are rather occupied in the denial of its existence, the very institutions which are most in a position to find a cure, are, ironically, not looking.

However in the absence of a definite cure, antibiotic therapy can be helpful. In fact, they can mean the difference between disability and good health. It has already been shown that longer treatment durations, although certainly not necessarily curative, may be more effective than shorter durations.70,71 In light of the foregoing totality of objective peer reviewed data, any medical professional who declares a persistently symptomatic Lyme patient cured simply because 4 weeks of antibiotic therapy has been completed, is, at best, sadly and grossly misinformed.

  1. Guy E C, Robertson J N, Cimmino M, Gern L, Moosmann Y, Rijpkema S G, Sambri V, Stanek G. European interlaboratory comparison of Lyme borreliosis serology. Zentralbl. Bakteriol. 1998 Mar;287(3):241-7.
  2. Lawrence C, Lipton RB, Lowy FD, Coyle PK Seronegative chronic relapsing neuroborreliosis. Eur. Neurol. 1995;35(2):113-7.
  3. Coyle PK, Schutzer SE, Deng Z, Krupp LB, Belman AL, Benach JL, Luft BJ Detection of Borrelia burgdorferi-specific antigen in antibody-negative cerebrospinal fluid in neurologic Lyme disease. Neurology. 1995 Nov;45(11):2010-5.
  4. Mouritsen CL, Wittwer CT, Litwin CM, Yang L, Weis JJ, Martins TB, Jaskowski TD, Hill HR Polymerase chain reaction detection of Lyme disease: correlation with clinical manifestations and serologic responses.Am. J. Clin. Pathol. 1996 May;105(5):647-54.
  5. Paul A. Arthritis, headache, facial paralysis. Despite negative laboratory tests Borrelia can still be the cause. MMW Fortschr. Med 2001 Feb 8;143(6):17.
  6. Pikelj F, Strle F, Mozina M. Seronegative Lyme disease and transitory atrioventricular block. Ann Intern Med 1989 Jul 1;111(1):90.
  7. Fraser DD, Kong LI, Miller FW. Molecular detection of persistent Borrelia burgdorferi in a man with dermatomyositis. Clin Exp Rheumatol 1992 Jul-Aug;10(4):387-90.
  8. Oksi J, Mertsola J, Reunanen M, Marjamaki M, Viljanen MK. Subacute multiple-site osteomyelitis caused by Borrelia burgdorferi. Clin Infect Dis 1994 Nov; 19(5): 891-6.
  9. Oksi J, Uksila J, Marjamaki M, Nikoskelainen J, Viljanen MK. Antibodies against whole sonicated Borrelia burgdorferi spirochetes, 41-kilodalton flagellin, and P39 protein in patients with PCR- or culture-proven late Lyme borreliosis. J Clin Microbiol 1995 Sep; 33(9): 2260-4.
  10. Oksi J, Kalimo H, Marttila RJ, Marjamaki M, Sonninen P, Nikoskelainen J, Viljanen MK. Inflammatory brain changes in Lyme borreliosis. A report on three patients and review of literature. Brain 1996 Dec; 119 ( Pt 6): 2143-54.
  11. Reimers CD, de Koning J, Neubert U, Preac Mursic V, Koster JG, Muller Felber W, Pongratz DE, Duray PH. Borrelia burgdorferi myositis: report of eight patients. J Neurol 1993 May; 240(5): 278-83.
  12. Oksi J, Viljanen MK, Kalimo H, Peltonen R, Marttia R, Salomaa P, Nikoskelainen J, Budka H, Halonen P. Fatal encephalitis caused by concomitant infection with tick-borne encephalitis virus and Borrelia burgdorferi. Clin Infect Dis 1993 Mar; 16(3): 392-6.
  13. Vartiovaara I. Living with Lyme see comments. Lancet 1995 Apr 1; 345(8953): 842-4.
  14. Pfister HW, Preac-Mursic V, Wilske B, Einhaupl KM, Weinberger K. Latent Lyme neuroborreliosis: presence of Borrelia burgdorferi in the cerebrospinal fluid without concurrent inflammatory signs. Neurology. 1989 Aug;39(8):1118-20.
  15. Preac-Mursic V, Weber K, Pfister HW, Wilske B, Gross B, Baumann A, Prokop J. Survival of Borrelia burgdorferi in antibiotically treated patients with Lyme borreliosis. Infection. 1989 Nov-Dec;17(6):355-9.
  16. Peter O, Bretz AG, Zenhausern R, Roten H, Roulet E. Isolation of Borrelia burgdorferi in the cerebrospinal fluid of 3 children with neurological involvement. Schweiz Med Wochenschr 1993 Jan 13; 123(1-2): 14-9.
  17. Straubinger RK; Summers BA; Chang YF; Appel MJ. Persistence of Borrelia burgdorferi in experimentally infected dogs after antibiotic treatment. J Clin Microbiol, 1997 Jan, 35:1, 111-6.
  18. Straubinger R K; Summers B A; Chang Y F; Appel M J. Persistence of Borrelia burgdorferi in experimentally infected dogs after antibiotic treatment. J. Clin. Microbiol. 1997 Jan, 35:1, 111-6.
  19. Nocton J J; Dressler F; Rutledge B J; Rys P N; Persing D H; Steere A C. Detection of Borrelia burgdorferi DNA by polymerase chain reaction in synovial fluid from patients with Lyme arthritis N. Engl. J. Med. 1994 Jan, 330:4, 229-34.
  20. Bayer M E; Zhang L; Bayer M H. Borrelia burgdorferi DNA in the urine of treated patients with chronic Lyme disease symptoms. A PCR study of 97 cases. Infection. 1996 Sep, 24:5, 347-53.
  21. Priem S, Burmester GR, Kamradt T, Wolbart K, Rittig MG, Krause A Detection of Borrelia burgdorferi by polymerase chain reaction in synovial membrane, but not in synovial fluid from patients with persisting Lyme arthritis after antibiotic therapy. Ann. Rheum. Dis. 1998 Feb;57(2):118-21.
  22. Albert S, Schulze J, Riegel H, Brade V. Lyme arthritis in a 12-year-old patient after a latency period of 5 years. Infection 1999;27(4-5):286-8.
  23. Battafarano DF, Combs JA, Enzenauer RJ, Fitzpatrick JE. Chronic septic arthritis caused by Borrelia burgdorferi. Clin Orthop 1993 Dec(297): 238-41.
  24. Wiegand W. Eye manifestations in borreliosis--bilateral panuveitis with exudative retinal detachment. Fortschr Ophthalmol 1989;86(6):659-62.
  25. Cimmino MA, Azzolini A, Tobia F, Pesce CM. Spirochetes in the spleen of a patient with chronic Lyme disease. Am J Clin Pathol 1989 Jan;91(1):95-7.
  26. Meier P, Blatz R, Gau M, Spencker FB, Wiedemann P. Pars plana vitrectomy in Borrelia burgdorferi endophthalmitisGerman Klin Monatsbl Augenheilkd 1998 Dec;213(6):351-4.
  27. Hulinska D, Votypka J, Valesova M. Persistence of Borrelia garinii and Borrelia afzelii in patients with Lyme arthritis. Int J Med Microbiol Virol Parasitol Infect Dis 1999 Jul;289(3):301-18.
  28. Kirsch M, Ruben FL, Steere AC, Duray PH, Norden CW, Winkelstein A. Fatal adult respiratory distress syndrome in a patient with Lyme disease. JAMA 1988 May 13; 259(18): 2737-9.
  29. Schoen RT, Aversa JM, Rahn DW, Steere AC. Treatment of refractory chronic Lyme arthritis with arthroscopic synovectomy. Arthritis Rheum 1991 Aug; 34(8): 1056-60.
  30. Schmidli J, Hunziker T, Moesli P, Schaad UB. Cultivation of Borrelia burgdorferi from joint fluid three months after treatment of facial palsy due to Lyme borreliosis letter. J Infect Dis 1988 Oct; 158(4): 905-6.
  31. Hulinska D, Krausova M, Janovska D, Rohacova H, Hancil J, Mailer H. Electron microscopy and the polymerase chain reaction of spirochetes from the blood of patients with Lyme disease. Cent Eur J Public Health 1993 Dec; 1(2): 81-5.
  32. Haupl T, Hahn G, Rittig M, Krause A, Schoerner C, Schonherr U, Kalden JR, Burmester GR. Persistence of Borrelia burgdorferi in ligamentous tissue from a patient with chronic Lyme borreliosis.
  33. Arthritis Rheum 1993 Nov; 36(11): 1621-6.
  34. Preac Mursic V, Marget W, Busch U, Pleterski Rigler D, Hagl S Kill kinetics of Borrelia burgdorferi and bacterial findings in relation to the treatment of Lyme borreliosis. Infection. 1996 Jan-Feb;24(1):9-16.
  35. Pfister HW, Preac-Mursic V, Wilske B, Schielke E, Sorgel F, Einhaupl KMJ. Randomized comparison of ceftriaxone and cefotaxime in Lyme neuroborreliosis. Infect. Dis. 1991 Feb;163(2):311-8.
  36. Preac-Mursic V, Pfister HW, Spiegel H, Burk R, Wilske B, Reinhardt S, Bohmer R First isolation of Borrelia burgdorferi from an iris biopsy. J. Clin. Neuroophthalmol. 1993 Sep;13(3):155-61.
  37. Oksi J, Marjamaki M, Nikoskelainen J, et al. Borrelia burgdorferi detected by culture and PCR in clinical relapse of disseminated Lyme borreliosis. Ann Med. 1999 Jun;31(3):225-232.
  38. Phillips SE, Mattman LH, Hulinska D, Moayad H. A proposal for the reliable culture of Borrelia burgdorferi from patients with chronic Lyme disease, even from those previously aggressively treated. Infection. 1998 Nov-Dec;26(6):364-7.
  39. Honegr K, Hulinska D, Dostal V, Gebousky P, Hankova E, Horacek J, Vyslouzil L, Havlasova J. Persistence of Borrelia burgdorferi sensu lato in patients with Lyme borreliosis. Epidemiol Mikrobiol Imunol 2001 Feb;50(1):10-6.
  40. Amosova LI. An electron microscopic study of Borrelia in the body of the female ixodid tick Ixodes persulcatus. Parazitologiia May-Jun 2000;34(3):234-40.
  41. Alban PS; Johnson PW; Nelson DR. Serum-starvation-induced changes in protein synthesis and morphology of Borrelia burgdorferi. Microbiology Jan 2000;146 (Pt 1):119-27.
  42. Bruck DK; Talbot ML; Cluss RG; Boothby JT. Ultrastructural characterization of the stages of spheroplast preparation of Borrelia burgdorferi. J Microbiol. Methods, 1995 (23):219-228.
  43. Benach JL. Functional heterogeneity in the antibodies produced to Borrelia burgdorferi. Wiener Klinische Wochenschrift, Dec1999;10;111(22-23):985-9.
  44. Mursic VP; Wanner G; Reinhardt S; Wilske B; Busch U; Marget W. Formation and cultivation of Borrelia burgdorferi spheroplast L-form variants. Infection 1996; 24(3):218-26.
  45. Cluss RG; Goel AS; Rehm HL; Schoenecker JG; Boothby JT. Coordinate synthesis and turnover of heat shock proteins in Borrelia burgdorferi: degradation of DnaK during recovery from heat shock. Infection & Immunity, May1996;64(5):1736-43.
  46. Kersten A; Poitschek C; Rauch S; Aberer E. Effects of penicillin, ceftriaxone, and doxycycline on the morphology of Borrelia burgdorferi. Antimicrobial Agents & Chemotherapy 1995;39(5):1127-33.
  47. Aberer E; Koszik F; Silberer M. Why is chronic Lyme borreliosis chronic? Clinical Infectious Diseases, 25 (Suppl 1), 1997 S64-S70.
  48. Aberer E; Kersten A; Klade H; Poitschek C; Jurecka W. Heterogeneity of Borrelia burgdorferi in the skin. American Journal of Dermatopathology, 1996;18(6):571-9.
  49. Angelov L; Dimova P; Berbencova W. Clinical and laboratory evidence of the importance of the tick D. marginatus as a vector of B. burgdorferi in some areas of sporadic Lyme disease in Bulgaria. European Journal of Epidemiology. 1996;12(5):499-502.
  50. Schaller M; Neubert Ultrastructure of Borrelia burgdorferi after exposure to benzylpenicillin. Infection, 1994 22(6):401-406.
  51. Phillips SE; Mattman LH; Hulinska D; Moayad H. A proposal for the reliable culture of Borrelia burgdorferi from patients with chronic Lyme disease, even from those previously aggressively treated. Infection 1998; 26(6):364-7.
  52. Hulinska D; Bartak P; Hercogova J; Hancil J; Basta J; Schramlova J. Electron microscopy of Langerhans cells and Borrelia burgdorferi in Lyme disease patients. Zbl Bakt 1994;280:348-349.
  53. Nanagara R; Duray PH; Schumacher HR. Jr. Ultrastructural demonstration of spirochetal antigens in synovial fluid and synovial membrane in chronic Lyme disease: possible factors contributing to persistence of organisms. Human Pathology 1996;Vol 27(10):1025-34.
  54. Hulinska D; Jirous J; Valesova M; Hercogova J. Ultrastructure of Borrelia burgdorferi in tissues of patients with Lyme disease. J Basic Microbiol, 1989 29:73-83.
  55. MacDonald AB. Concurrent neocortical borreliosis and Alzheimer's disease: Demonstration of a spirochetal cyst form. Annals of the New York Academy of Sciences, 1988 539:468-470.
  56. Brorson O; Brorson SH. Transformation of cystic forms of Borrelia burgdorferi to normal mobile spirochetes. Infection, 1997 25:240-6.
  57. Brorson O; Brorson. In vitro conversion of Borrelia burgdorferi to cystic forms in spinal fluid, and transformation to mobile spirochetes by incubation in BSK-H medium. Infection 1998; 26(3):144-50.
  58. Gruntar I, Malovrh T, Murgia R, Cinco M. Conversion of Borrelia garinii cystic forms to motile spirochetes in vivo. APMIS 2001 May;109(5):383-8.
  59. Zajkowska JM; Hermanowska-Szpakowicz T; Pancewicz SA; Kondrusik M. Selected aspects of immunopathogenesis in Lyme disease. Pol Merkuriusz Lek, 2000 9(50):579-83.
  60. Zajkowska JM; Hermanowska-Szpakowicz T; Kondrusik M; Pancewicz SA. Neurologic syndromes in Lyme disease. Pol Merkuriusz Lek, 2000 9(50):584-8.
  61. Brorson O; Brorson. A rapid method for generating cystic forms of Borrelia burgdorferi, and their reversal to mobile spirochetes. APMIS 1998;106(12):1131-1141.
  62. Wolf V; Wecke J. Formation of multiple treponemes. Zbl Bakt, 1994 280:297-303.
  63. Brorson O; Brorson 1999 An in vitro study of the susceptibility of mobile and cystic forms of Borrelia burgdorferi to metronidazole.APMIS, 107(6):566-576.
  64. Ma Y, Sturrock A, Weis JJ. Intracellular localization of Borrelia burgdorferi within human endothelial cells. Infect Immun 1991 Feb;59(2):671-8.
  65. Klempner MS, Noring R, Rogers RA. Invasion of human skin fibroblasts by the Lyme disease spirochete, Borrelia burgdorferi. J Infect Dis 1993 May;167(5):1074-81.
  66. Dorward DW, Fischer ER, Brooks DM. Invasion and cytopathic killing of human lymphocytes by spirochetes causing Lyme disease. Clin Infect Dis 1997 Jul;25 Suppl 1:S2-8.
  67. Montgomery RR, Nathanson MH, Malawista SE. The fate of Borrelia burgdorferi, the agent for Lyme disease, in mouse macrophages. Destruction, survival, recovery. J Immunol 1993 Feb 1;150(3):909-15.
  68. Girschick HJ, Huppertz HI, Russmann H, Krenn V, Karch H. Intracellular persistence of Borrelia burgdorferi in human synovial cells. Rheumatol Int 1996;16(3):125-32.
  69. Georgilis K, Peacocke M, Klempner MS. Fibroblasts protect the Lyme disease spirochete, Borrelia burgdorferi, from ceftriaxone in vitro. J Infect Dis 1992 Aug;166(2):440-4.
  70. Brouqui P, Badiaga S, Raoult D. Eucaryotic cells protect Borrelia burgdorferi from the action of penicillin and ceftriaxone but not from the action of doxycycline and erythromycin. Antimicrob Agents Chemother 1996 Jun;40(6):1552-4.
  71. Petrovic M, Vogelaers D, Van Renterghem L, Carton D, De Reuck J, Afschrift M. Lyme borreliosis--a review of the late stages and treatment of four cases. Acta. Clin. Belg. 1998 Jun;53(3):178-83.
  72. Donta S T. Tetracycline therapy for chronic Lyme disease. Clin. Infect. Dis. 1997 Jul;25 Suppl 1:S52-6.

  73. LYME DISEASE BABESIA BARTONELLA BEST DOCTORS 26 BOOKS/27 PAPERS  TREATMENT ILADS IGENEX MOLD ILLNESS BIOTOXINS JAMES SCHALLER